In contrast, there was no noticeable change in tumor burden between TC-1 tumor-bearing mice treated with isotype or αIL6 (Fig. 4E and F), suggesting that blockade of IL6 has the potential to limit development and progression of HPV − HNSCC. Here, IL6 is linked to neoplasm.